Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Regulatory Neutral

DIAGNOS Submits Modified and Updated Health Canada Licence Application for CARA System Platform

Pre-revenue medical AI developer navigating regulatory hurdles while burning through cash reserves.

By The Northwire Desk — AI Analysis Jun 16, 2026 · 09:15 ADK · 0.195 Diagnos Inc.
Executive Summary
  • Diagnos Inc. submitted a modified and updated Class II medical device licence application for its CARA System platform to Health Canada on June 16, 2026.
  • The submission incorporates advanced image analysis and interpretability tools designed to integrate into optometrists' clinical workflows for fundus photography analysis.
  • Management confirms strict adherence to Health Canada's guidance received in fall 2025 and anticipates a positive regulatory outcome.
  • The platform currently detects early signs of age-related macular degeneration (AMD) and diabetic retinopathy.
  • Trading tickers: TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A.
Material Impact
  • The submission is a standard regulatory milestone, not a commercialization event. It does not generate immediate revenue or alter the cash burn trajectory.
  • The market likely already priced in the June submission target, as it was previously highlighted in the June 5 flash report and April 8 update.
  • No change to the company's fundamental risk profile: still pre-revenue, pre-approval, and reliant on external financing to continue operations.
  • Sentiment may see a minor, short-lived boost from the submission confirmation, but the lack of an approval decision or commercial partnership activation limits material upside.
ADK · Price
Company Overview
  • Diagnos Inc. is a Canadian medical technology company developing the CARA System, a cloud-based AI platform for retinal image analysis.
  • The platform is designed to detect early signs of systemic and ocular diseases, including diabetic retinopathy and age-related macular degeneration, using standard fundus cameras.
  • The company targets optometrist clinics and chains globally, citing an estimated 1.1 million optometrists and an $11 billion addressable market.
  • Commercialization is contingent upon securing regulatory approvals in Canada, the United States, and Saudi Arabia.
  • The company has established strategic relationships with major optical industry participants, including EssilorLuxottica and IRIS The Visual Group, to accelerate adoption post-approval.
Read the original news release →

More from Diagnos Inc.

Jun 18, 2026 · 12:00

Cash-preserving debt settlement underscores ongoing liquidity constraints ahead of critical CARA regulatory milestones.

Financings Jun 05, 2026 · 10:00

DIAGNOS Inc. Awaits Health Canada Catalyst as Cash Runway Narrows Ahead of Dilutive Financing

Regulatory Apr 08, 2026 · 12:14

Regulatory timeline update keeps CARA on track, no surprise for investors

Production / Operations Mar 05, 2026 · 18:26

Diagnos to amend convertible debenture, warrant terms

Financings Mar 05, 2026 · 15:45

DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants

Financings Feb 04, 2026 · 20:07

Diagnos expects to receive $1M in federal investments

Other